Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2019 | QoL in patients undergoing CAR T-cell therapy versus transplantation

Surbhi Sidana • 3 Jun 2019
ASCO 2019
Acute Lymphoblastic Leukemia B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Leukemia Lymphoma CAR-T

In this video, Surbhi Sidana, MD, of the Mayo Clinic, Rochester, MN, discusses the QoL in patients undergoing CAR T-cell therapy versus transplantation. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Surbhi Sidana

Managing toxicities associated with immunotherapy in multiple myeloma
1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
Ide-cel therapy for multiple myeloma with renal impairment
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
An overview of the toxicities associated with immunotherapy in multiple myeloma
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Surbhi Sidana • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Surbhi Sidana • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Surbhi Sidana • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Surbhi Sidana • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals